Literature DB >> 32428441

Immunity to Cas9 as an Obstacle to Persistent Genome Editing.

Veronica Gough1, Charles A Gersbach2.   

Abstract

Mesh：

Year:  2020        PMID： 32428441      PMCID： PMC7264432          DOI： 10.1016/j.ymthe.2020.05.007

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  18 in total

1.  Somatic Gene Editing of GUCY2D by AAV-CRISPR/Cas9 Alters Retinal Structure and Function in Mouse and Macaque.

Authors:  K Tyler McCullough; Sanford L Boye; Diego Fajardo; Kaitlyn Calabro; James J Peterson; Christianne E Strang; Dibyendu Chakraborty; Sebastian Gloskowski; Scott Haskett; Steven Samuelsson; Haiyan Jiang; C Douglas Witherspoon; Paul D Gamlin; Morgan L Maeder; Shannon E Boye
Journal:  Hum Gene Ther       Date:  2018-12-20       Impact factor: 5.695

2.  High prevalence of Streptococcus pyogenes Cas9-reactive T cells within the adult human population.

Authors:  Dimitrios L Wagner; Leila Amini; Desiree J Wendering; Lisa-Marie Burkhardt; Levent Akyüz; Petra Reinke; Hans-Dieter Volk; Michael Schmueck-Henneresse
Journal:  Nat Med       Date:  2018-10-29       Impact factor: 53.440

3.  In vivo genome editing using Staphylococcus aureus Cas9.

Authors:  F Ann Ran; Le Cong; Winston X Yan; David A Scott; Jonathan S Gootenberg; Andrea J Kriz; Bernd Zetsche; Ophir Shalem; Xuebing Wu; Kira S Makarova; Eugene V Koonin; Phillip A Sharp; Feng Zhang
Journal:  Nature       Date:  2015-04-01       Impact factor: 49.962

Review 4.  Emerging Issues in AAV-Mediated In Vivo Gene Therapy.

Authors:  Pasqualina Colella; Giuseppe Ronzitti; Federico Mingozzi
Journal:  Mol Ther Methods Clin Dev       Date:  2017-12-01       Impact factor: 6.698

5.  AAV-CRISPR Gene Editing Is Negated by Pre-existing Immunity to Cas9.

Authors:  Ang Li; Mark R Tanner; Ciaran M Lee; Ayrea E Hurley; Marco De Giorgi; Kelsey E Jarrett; Timothy H Davis; Alexandria M Doerfler; Gang Bao; Christine Beeton; William R Lagor
Journal:  Mol Ther       Date:  2020-04-19       Impact factor: 11.454

6.  A Self-Deleting AAV-CRISPR System for In Vivo Genome Editing.

Authors:  Ang Li; Ciaran M Lee; Ayrea E Hurley; Kelsey E Jarrett; Marco De Giorgi; Weiqi Lu; Karol S Balderrama; Alexandria M Doerfler; Harshavardhan Deshmukh; Anirban Ray; Gang Bao; William R Lagor
Journal:  Mol Ther Methods Clin Dev       Date:  2018-12-06       Impact factor: 6.698

7.  Multifunctional CRISPR-Cas9 with engineered immunosilenced human T cell epitopes.

Authors:  Shayesteh R Ferdosi; Radwa Ewaisha; Farzaneh Moghadam; Sri Krishna; Jin G Park; Mo R Ebrahimkhani; Samira Kiani; Karen S Anderson
Journal:  Nat Commun       Date:  2019-04-23       Impact factor: 14.919

8.  CRISPR-Cas9-Mediated Genome Editing Increases Lifespan and Improves Motor Deficits in a Huntington's Disease Mouse Model.

Authors:  Freja K Ekman; David S Ojala; Maroof M Adil; Paola A Lopez; David V Schaffer; Thomas Gaj
Journal:  Mol Ther Nucleic Acids       Date:  2019-07-26

9.  Immune-orthogonal orthologues of AAV capsids and of Cas9 circumvent the immune response to the administration of gene therapy.

Authors:  Ana M Moreno; Nathan Palmer; Fernando Alemán; Genghao Chen; Andrew Pla; Ning Jiang; Wei Leong Chew; Mansun Law; Prashant Mali
Journal:  Nat Biomed Eng       Date:  2019-07-22       Impact factor: 25.671

10.  A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice.

Authors:  Yang Yang; Lili Wang; Peter Bell; Deirdre McMenamin; Zhenning He; John White; Hongwei Yu; Chenyu Xu; Hiroki Morizono; Kiran Musunuru; Mark L Batshaw; James M Wilson
Journal:  Nat Biotechnol       Date:  2016-02-01       Impact factor: 54.908
View more
  8 in total

Review 1.  Prospects of viral vector-mediated delivery of sequences encoding anti-HBV designer endonucleases.

Authors:  Ridhwaanah Jacobs; Prashika Singh; Tiffany Smith; Patrick Arbuthnot; Mohube Betty Maepa
Journal:  Gene Ther       Date:  2022-05-24       Impact factor: 5.250

Review 2.  Therapeutic Genome Editing and In Vivo Delivery.

Authors:  Amanda Catalina Ramirez-Phillips; Dexi Liu
Journal:  AAPS J       Date:  2021-06-02       Impact factor: 4.009

Review 3.  CRISPR/Cas9 ribonucleoprotein-mediated genome and epigenome editing in mammalian cells.

Authors:  Hanan Bloomer; Jennifer Khirallah; Yamin Li; Qiaobing Xu
Journal:  Adv Drug Deliv Rev       Date:  2021-12-20       Impact factor: 15.470

Review 4.  New Directions in Pulmonary Gene Therapy.

Authors:  Amber Vu; Paul B McCray
Journal:  Hum Gene Ther       Date:  2020-09       Impact factor: 4.793

Review 5.  Potential Use of CRISPR/Cas13 Machinery in Understanding Virus-Host Interaction.

Authors:  Mahmoud Bayoumi; Muhammad Munir
Journal:  Front Microbiol       Date:  2021-11-26       Impact factor: 5.640

6.  Programmable RNA base editing with a single gRNA-free enzyme.

Authors:  Wenjian Han; Wendi Huang; Tong Wei; Yanwen Ye; Miaowei Mao; Zefeng Wang
Journal:  Nucleic Acids Res       Date:  2022-08-27       Impact factor: 19.160

7.  Cross-species evolution of a highly potent AAV variant for therapeutic gene transfer and genome editing.

Authors:  Katherine E Simon; Leo O Blondel; Trevor J Gonzalez; Marco M Fanous; Angela L Roger; Maribel Santiago Maysonet; Garth W Devlin; Timothy J Smith; Daniel K Oh; L Patrick Havlik; Ruth M Castellanos Rivera; Jorge A Piedrahita; Mai K ElMallah; Charles A Gersbach; Aravind Asokan
Journal:  Nat Commun       Date:  2022-10-10       Impact factor: 17.694

8.  Rapid interrogation of cancer cell of origin through CRISPR editing.

Authors:  Weiran Feng; Zhen Cao; Pei Xin Lim; Huiyong Zhao; Hanzhi Luo; Ninghui Mao; Young Sun Lee; Aura Agudelo Rivera; Danielle Choi; Chao Wu; Teng Han; Rodrigo Romero; Elisa de Stanchina; Brett S Carver; Qiao Wang; Maria Jasin; Charles L Sawyers
Journal:  Proc Natl Acad Sci U S A       Date:  2021-08-10       Impact factor: 11.205
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.